Stay updated on Pembrolizumab in Renal Cell Carcinoma Adjuvant Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Renal Cell Carcinoma Adjuvant Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Renal Cell Carcinoma Adjuvant Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Revision: v3.3.2 was added and Revision: v3.3.1 was removed. This update changes only metadata/version information and does not affect study details or page functionality.
    Difference
    0.0%
    Check dated 2025-11-30T06:08:06.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    Publications section now includes notes that publications are provided voluntarily and auto-filled from PubMed. The page revision is shown as Revision: v3.3.1.
    Difference
    0.0%
    Check dated 2025-11-23T00:28:57.000Z thumbnail image
  3. Check
    22 days ago
    Change Detected
    Summary
    The lapse in government funding notice has been removed from the page, and other content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-15T15:06:38.000Z thumbnail image
  4. Check
    29 days ago
    No Change Detected
  5. Check
    36 days ago
    Change Detected
    Summary
    Publications and results related to KEYNOTE-564 were added, including a 2024 NEJM article, and the study record dates were updated.
    Difference
    0.1%
    Check dated 2025-11-01T07:29:45.000Z thumbnail image
  6. Check
    65 days ago
    Change Detected
    Summary
    Added a time-sensitive operating status notice and funding-related disclaimer, and updated the version to v3.2.0 (removing v3.1.0).
    Difference
    1%
    Check dated 2025-10-03T08:50:29.000Z thumbnail image
  7. Check
    72 days ago
    Change Detected
    Summary
    The page updated to v3.1.0 and removed several MedlinePlus drug-safety topics (Drug Safety, Substandard Drugs, Counterfeit Drugs), signaling a reorientation or narrowing of content rather than new information.
    Difference
    0.3%
    Check dated 2025-09-26T04:24:47.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Renal Cell Carcinoma Adjuvant Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Renal Cell Carcinoma Adjuvant Clinical Trial page.